The ACCORD study will have in excess of 5000 patients with type 2 diabetes on the combination of fenofibrate plus simvastatin vs.
simvastatin alone. The additive effects of statin–fibrate combinations on lipid profiles have been documented. The atorvastatin–fenofibrate combination has been shown to have a. The results showed that fenofibrate plus simvastatin combination therapy was associated with a non-significant 8% relative risk reduction in the.
Addition of fenofibrate to statin therapy might represent a viable treatment option for patients whose high risk for coronary heart disease is not controlled by a. Further study is needed, but adding fenofibrate to statins may decrease cardiovascular disease events in certain patients with type 2 diabetes.
© 2018 ekoservis-kuban.ru